Koers Mabvax Therapeutics Holdings Inc OTC Bulletin Board
Aandelen
MBVX
US55414P1084
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2016 | 148K 136K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,22 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,6 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,43 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 431K | Nettoschuld 2017 | 2,48 mln. 2,28 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,17% | 127 mld. | |
+24,67% | 117 mld. | |
+25,44% | 27,67 mld. | |
-17,74% | 20,33 mld. | |
-15,17% | 16,79 mld. | |
-15,21% | 15,63 mld. | |
+11,91% | 14,84 mld. | |
-47,10% | 14,65 mld. | |
+54,50% | 14,43 mld. |
- Beurs
- Aandelen
- Koers MBVXQ
- Koers MBVX